Research Opportunities

  • Friday, September 18, 2020

Mitsubishi Phase 3 EPP Trial Sites Open

?Active study sites now include:

  • Columbus, OH
  • Boston, MA
  • Winston-Salem, NC
  • More locations coming soon. Contact the APF for more information

MT-7117 Clinical Trial
Phase 3 Clinical Trial
Participants with EPP or XLP are needed!

Trial Description: A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, And Tolerability of MT-7117 in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).

Treatment: Oral medication (pills), once daily in the morning with or without food Duration: 26 weeks plus optional 26 week double-blinded extension.

Endpoint: Increased pain free light exposure in adults and adolescents with a history of phototoxic reactions from EPP or XLP. 

Study Sites: There will be 12 study sites in the US, followed by global study sites across multiple countries. 

Age Range: Patients age 12 - 75

Travel: Will be included and will be arranged by a concierge service trained on EPP/XLP.

Please contact the American Porphyria Foundation for more information and we will connect you with a study site nearest you.

Email OR
call 866-APF-3635 (301-347-7166).